Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sotirios Tsimboukis"'
Autor:
Vassiliki Chasapi, Kostas N. Syrigos, Eleni M. Karapanagiotou, Christina Antoniou, Athina Matekovits, Kalliopi D. Dilana, Theognosia Vergou, Sotirios Tsimboukis, Alexander J. Stratigos
Publikováno v:
Journal of the American Academy of Dermatology. 63:e56-e58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::265e5f1df9f87c6397d0cd40d7542bc7
https://doi.org/10.1016/j.jaad.2009.11.589
https://doi.org/10.1016/j.jaad.2009.11.589
Autor:
Irene Merikas, Eleni M. Karapanagiotou, Sotirios Tsimboukis, Muhammad Wasif Saif, Kostas N. Syrigos
Publikováno v:
Clinical lung cancer. 10(2)
The human epidermal growth factor receptor (EGFR) signaling is overexpressed in many solid malignancies, making it an appealing target for biologic agents. A number of agents that target this receptor are in use or in development. A specific adverse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef71325cb35e7d49cf5aa47be38d0a21
https://pubmed.ncbi.nlm.nih.gov/19362953
https://pubmed.ncbi.nlm.nih.gov/19362953
Publikováno v:
JOP : Journal of the pancreas. 9(3)
Erlotinib is a tyrosine kinase inhibitor with anti epidermal growth factor receptor activity, approved as first line treatment concurrently administrated with gemcitabine for locally advanced unresectable or metastatic pancreatic cancer. One of the m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ddfb290c9abc8578e62abab95ebfaf86
https://pubmed.ncbi.nlm.nih.gov/18469438
https://pubmed.ncbi.nlm.nih.gov/18469438